Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359474 | 0.81 | RAB9A (0.44) | SMN1; SMN2ALDH1A1NPC1POLBMAPT | |
| SCHEMBL13359471 | 0.76 | HPGD (0.42) | SMN1; SMN2KDM4ELMNANPC1MAPT | |
| SCHEMBL13325221 | 0.76 | ATM (0.48) | ATMKMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13359491 | 0.74 | CACNA1G (0.57) | KMT2AALDH1A1LMNATSHR | |
| SCHEMBL13359440 | 0.73 | BRD4 (0.46) | KMT2ASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL13359538 | 0.72 | CYP11B1 (0.46) | KMT2ASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL13359536 | 0.72 | CASP3 (0.43) | SMN1; SMN2ALDH1A1LMNANPC1MAPT | |
| SCHEMBL13359484 | 0.72 | ADORA1 (0.46) | KMT2ASMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL13359443 | 0.69 | ELOVL1 (0.52) | SMN1; SMN2ALDH1A1LMNANPC1POLB | |
| SCHEMBL13359475 | 0.68 | POLB (0.53) | KMT2ASMN1; SMN2ALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | ATM 2432/4885KMT2A 2837/4885SMN1; SMN2 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.